Mast-cell interleukin-1β, neutrophil interleukin-17 and epidermal antimicrobial proteins in the neutrophilic urticarial dermatosis in Schnitzler's syndrome

British Journal of Dermatology

Volumn 173, Issue 2, 2015, Pages 448-456

  De Koning, H D ^a,b,c   Van Vlijmen Willems, I M J J ^a   Rodijk Olthuis, D ^a   Van Der Meer, J W M ^a,c   Zeeuwen, P L J M ^a,b,c   Simon, A ^a,c   Schalkwijk, J ^a,b,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c N4i Centre for Immunodeficiency and Autoinflammation   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; INTERLEUKIN 17; INTERLEUKIN 1BETA; MESSENGER RNA; POLYINOSINIC POLYCYTIDYLIC ACID; POLYPEPTIDE ANTIBIOTIC AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; BETA DEFENSIN; DEFB4A PROTEIN, HUMAN; IL17A PROTEIN, HUMAN; INTERFERON INDUCING AGENT; PROTEIN S 100; S100A7 PROTEIN, HUMAN;

ARTICLE; CELL INFILTRATION; CINCA SYNDROME; CLINICAL ARTICLE; COLD CONTACT URTICARIA; CONTROLLED STUDY; DELAYED PRESSURE URTICARIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INVESTIGATIVE PROCEDURES; KERATINOCYTE; MAST CELL; NEUTROPHIL; NEUTROPHILIC URTICARIAL DERMATOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHNITZLER SYNDROME; SKIN BIOPSY; SKIN CELL; SKIN DEFECT; SKIN DISEASE; URTICARIA; CASE CONTROL STUDY; CELL CULTURE; FEMALE; MALE; METABOLISM;

ANTIMICROBIAL CATIONIC PEPTIDES; BETA-DEFENSINS; CASE-CONTROL STUDIES; CELLS, CULTURED; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; FEMALE; HUMANS; INTERFERON INDUCERS; INTERLEUKIN-17; INTERLEUKIN-1BETA; KERATINOCYTES; MALE; MAST CELLS; NEUTROPHILS; POLY I-C; S100 PROTEINS; SCHNITZLER SYNDROME; URTICARIA;

EID: 84941184977     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13857     Document Type: Article

References (31)

1. de Koning HD, Bodar EJ, van der Meer JW, Simon A,. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 2007; 37: 137-48.
2. Lipsker D, Veran Y, Grunenberger F, et al,. The Schnitzler syndrome. Four new cases and review of the literature. Medicine (Baltimore) 2001; 80: 37-44.
3. Simon A, Asli B, Braun-Falco M, et al,. Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy 2013; 68: 562-8.
4. Krause K, Weller K, Stefaniak R, et al,. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy 2012; 67: 943-50.
5. de Koning HD, Schalkwijk J, van der Ven-Jongekrijg J, et al,. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome. Ann Rheum Dis 2013; 72: 1634-8.
6. Ryan JG, de Koning HD, Beck LA, et al,. IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. J Allergy Clin Immunol 2008; 121: 260-2.
7. Besada E, Nossent H,. Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler's syndrome: a case report and literature review. Clin Rheumatol 2010; 29: 567-71.
8. Cascavilla N, Bisceglia M, D'Arena G,. Successful treatment of Schnitzler's syndrome with anakinra after failure of rituximab trial. Int J Immunopathol Pharmacol 2010; 23: 633-6.
9. de Koning HD, Bodar EJ, Simon A, et al,. Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Ann Rheum Dis 2006; 65: 542-4.
10. Klemmer N, Lenain P, Balguerie X, Le Loët X,. Effectiveness of anti-IL1 in Schnitzler's syndrome. Joint Bone Spine 2007; 74: 509-10.
11. Kluger N, Rivière S, Guillot B, Bessis D,. Efficacy of interleukin 1 receptor antagonist (anakinra) on a refractory case of Schnitzler's syndrome. Acta Derm Venereol 2008; 88: 287-8.
12. Martinez-Taboada VM, Fontalba A, Blanco R, Fernández-Luna JL,. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al. Arthritis Rheum 2005; 52: 2226-7.
13. Vanderschueren S, Knockaert D,. Canakinumab in Schnitzler syndrome. Semin Arthritis Rheum 2013; 42: 413-16.
14. de Koning HD, Schalkwijk J, van der Meer JW, Simon A,. Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome. J Allergy Clin Immunol 2011; 128: 1352-4.
15. Kieffer C, Cribier B, Lipsker D,. Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine (Baltimore) 2009; 88: 23-31.
16. Nakamura Y, Kambe N, Saito M, et al,. Mast cells mediate neutrophil recruitment and vascular leakage through the NLRP3 inflammasome in histamine-independent urticaria. J Exp Med 2009; 206: 1037-46.
17. de Koning HD, van Gijn ME, Stoffels M, et al,. Myeloid lineage-restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome. J Allergy Clin Immunol 2015; 135: 561-4.
18. Volz T, Wolbing F, Fischer J, et al,. Dermal interleukin-1 expression and effective and long-lasting therapy with interleukin-1 receptor antagonist anakinra in Schnitzler syndrome. Acta Derm Venereol 2012; 92: 393-4.
19. de Jongh GJ, Zeeuwen PL, Kucharekova M, et al,. High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J Invest Dermatol 2005; 125: 1163-73.
20. van Ruissen F, Jansen BJ, de Jongh GJ, et al,. A partial transcriptome of human epidermis. Genomics 2002; 79: 671-8.
21. -ΔΔCT method. Methods 2001; 25: 402-8.
22. Wingens M, van Bergen BH, Hiemstra PS, et al,. Induction of SLPI (ALP/HUSI-I) in epidermal keratinocytes. J Invest Dermatol 1998; 111: 996-1002.
23. Zeeuwen PL, de Jongh GJ, Rodijk-Olthuis D, et al,. Genetically programmed differences in epidermal host defense between psoriasis and atopic dermatitis patients. PLoS ONE 2008; 3: e2301.
24. Keijsers RR, Hendriks AG, van Erp PE, et al,. In vivo induction of cutaneous inflammation results in the accumulation of extracellular trap-forming neutrophils expressing RORγt and IL-17. J Invest Dermatol 2014; 134: 1276-84.
25. Agostini L, Martinon F, Burns K, et al,. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20: 319-25.
26. Nakamura Y, Franchi L, Kambe N, et al,. Critical role for mast cells in interleukin-1β-driven skin inflammation associated with an activating mutation in the Nlrp3 protein. Immunity 2012; 37: 85-95.
27. Zeeuwen PL, Boekhorst J, van den Bogaard EH, et al,. Microbiome dynamics of human epidermis following skin barrier disruption. Genome Biol 2012; 13: R101.
28. Launay D, Dutoit-Lefevre V, Faure E, et al,. Effect of in vitro and in vivo anakinra on cytokines production in Schnitzler syndrome. PLoS ONE 2013; 8: e59327.
29. Pizzirani C, Falzoni S, Govoni M, et al,. Dysfunctional inflammasome in Schnitzler's syndrome. Rheumatology (Oxford) 2009; 48: 1304-8.
30. Hoffman HM, Rosengren S, Boyle DL, et al,. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004; 364: 1779-85.
31. Yamauchi A, Iwata H, Ohnishi H, et al,. Interleukin-17 expression in the urticarial rash of familial cold autoinflammatory syndrome: a case report. Br J Dermatol 2010; 163: 1351-3.